Fluticasone Propionate
FDA-approved product (ointment, topical), marketed as Armonair Digihaler, Armonair Respiclick, Cutivate and 9 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Allergic rhinitis
- Asthma
- Atopic eczema
- Chronic bronchitis
- Chronic obstructive pulmonary disease
- Emphysema
- Nasal Cavity Polyp
- Nasal congestion
- Nasal polyposis
- Seasonal allergic rhinitis
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fluticasone Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
NCT00736801 · start 2005-09
Registered record
- Registry ID
- NCT00736801
- Conditions
- Allergic Asthma
- Interventions
- Salmeterol and Salmeterol / Fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2007-04
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic AsthmaInterventionSalmeterol and Salmeterol / FluticasonePhaseNot applicableRegistry statusCompletedThe Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
NCT00402207 · start 2005-08
Registered record
- Registry ID
- NCT00402207
- Conditions
- Asthma
- Interventions
- extrafine HFA-beclomethasone; HFA-fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-08
- Completion
- 2006-10
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionextrafine HFA-beclomethasone; HFA-fluticasonePhaseNot applicableRegistry statusCompletedProtopic Ointment in Adult Atopic Eczema of the Face
NCT00690105 · start 2004-02
Registered record
- Registry ID
- NCT00690105
- Conditions
- Dermatitis, Atopic
- Interventions
- tacrolimus 0.1%; fluticasone 0.005 %
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2005-07
- Enrolment
- 577
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDermatitis, AtopicInterventiontacrolimus 0.1%; fluticasone 0.005 %PhasePhase 4Registry statusCompletedComparison of Two Treatment Regimens in Asthmatic Patients
NCT01488773 · start 1995-04
Registered record
- Registry ID
- NCT01488773
- Conditions
- Asthma
- Interventions
- first prescription of montelukast; first prescription of salmeterol
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1995-04
- Completion
- 2006-06
- Enrolment
- 132
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionfirst prescription of montelukast; first prescription of salmeterolPhaseNot recordedRegistry statusCompletedExpanded Access Protocol for Patients With Eosinophilic Esophagitis
NCT05095116
Registered record
- Registry ID
- NCT05095116
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011 3 mg HS
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEosinophilic EsophagitisInterventionAPT-1011 3 mg HSPhaseNot recordedRegistry statusNo longer available